Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of JNJ-78934804 versus guselkumab in moderately to severely active ulcerative colitis
MOH_2026-05-20_015842Phase 3Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of guselkumab + golimumab, guselkumab and golimumab in autoimmune colitis (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Efficacy of JNJ-78934804 compared with guselkumab at week 48. Planned start May 2026; status: not yet recruiting.
02
Drugs
guselkumab + golimumabguselkumabgolimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2026-05-20_015842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-05-20_015842.